Half of lymphoma patients alive three years after Gilead cell therapy treatment: study
(Reuters) – Nearly half of lymphoma patients treated with Gilead Sciences Inc’s Yescarta were alive at least three years after…
Cancer patients, survivors face increased risk of heart disease deaths
(Reuters Health) – Many cancer patients and survivors die from heart disease rather than from their tumors, especially if they…
GSK builds oncology pipeline as drug shown to help myeloma patients
(Reuters) – GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out…
Medicare to cover expensive cancer cell therapies
FILE PHOTO: A Gilead Sciences, Inc. office is shown in Foster City, California, U.S. May 1, 2018. REUTERS/Stephen Lam (Reuters)…
Many deadly common cancers get little charity funding
(Reuters Health) – Many of the most common and lethal cancers get the fewest research dollars from fundraising advocacy groups,…
FDA declines to approve Daiichi Sankyo’s blood cancer treatment
(Reuters) – Japan’s Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its…
Brazil health agency concludes safety evaluation of weedkiller glyphosate
BRASILIA (Reuters) – Brazil’s health agency has concluded a re-evaluation of the safety of the weedkiller glyphosate, the most widely-used…
Johnson & Johnson’s multiple myeloma drug reduces risk of death in late-stage study
FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California, U.S., January 24, 2017. REUTERS/Mike Blake (Reuters) –…
Cancer diagnosis tied to increased risk of diabetes
(Reuters Health) – People who get diagnosed with cancer may be more likely to develop diabetes, a Korean study suggests.…